SCHEMBL11943577

SCHEMBL11943577

CCCCCSc1c(N2CCN(S(C)(=O)=O)CC2)cnn(-c2ccccc2)c1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.61
DCTPP1 Q9H773 3/20 0.61
MAPT P10636 6/20 0.56
SMN1; SMN2 Q16637 6/20 0.56
LMNA P02545 5/20 0.56
NPSR1 Q6W5P4 4/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44
PPARG P37231 3/20 0.44
NCOA2 Q15596 3/20 0.44
NCOA1 Q15788 3/20 0.44
RXFP1 Q9HBX9 2/20 0.44
BLM P54132 1/20 0.44
RAB9A P51151 5/20 0.42
NPC1 O15118 4/20 0.42
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
CA12 O43570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943565 0.99 ALDH1A1 (0.60) ALDH1A1DCTPP1MAPTSMN1; SMN2LMNA
SCHEMBL11943578 0.99 ALDH1A1 (0.60) ALDH1A1DCTPP1MAPTSMN1; SMN2LMNA
SCHEMBL11943562 0.88 MAPT (0.56) ALDH1A1DCTPP1MAPTSMN1; SMN2LMNA
SCHEMBL11943570 0.86 ALDH1A1 (0.44) ALDH1A1DCTPP1MAPTSMN1; SMN2LMNA
SCHEMBL11943568 0.85 MAPT (0.48) ALDH1A1DCTPP1MAPTSMN1; SMN2LMNA
SCHEMBL11944984 0.80 ALDH1A1 (0.61) ALDH1A1DCTPP1MAPTSMN1; SMN2LMNA
SCHEMBL11944233 0.76 ALDH1A1 (0.58) ALDH1A1DCTPP1MAPTSMN1; SMN2LMNA
SCHEMBL11944881 0.76 MAPT (0.38) ALDH1A1DCTPP1MAPTSMN1; SMN2LMNA
SCHEMBL11943569 0.76 MAPT (0.38) ALDH1A1DCTPP1MAPTSMN1; SMN2LMNA
SCHEMBL11943095 0.73 MAPT (0.47) ALDH1A1DCTPP1MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA ALDH1A1 2437/4885DCTPP1 625/4885MAPT 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.